Safety profile of telaprevir-based triple therapy in elderly patients: A real-world retrospective cohort study.
Abstract
To compare the rate of treatment discontinuation due to adverse events for telaprevir-based triple (T/PR) and pegylated interferon-alfa-2b and ribavirin (PR) therapy for the treatment of hepatitis C virus (HCV) infection in patients over the age of 65 years, in Japan.Retrospective analysis of the health data of patients over the age of 65 years treated for a HCV infection genotype 1 using T/PR or PR therapy, from 38 prefectures in Japan. The primary outcome was the rate of treatment discontinuation due to adverse events for T/PR and PR. The secondary outcome was to evaluate the prevalence and type...
Source: Biological and Pharmaceutical Bulletin - June 9, 2017 Category: Drugs & Pharmacology Authors: Akutagawa M, Ide K, Kawasaki Y, Yamanaka M, Iketani R, Yamada H, Masaki N Tags: Biol Pharm Bull Source Type: research
[Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
Authors: Şanlıdağ T, Sayan M, Akçalı S, Kasap E, Buran T, Arıkan A
Abstract
Direct-acting antiviral agents (DAA) such as NS3 protease inhibitors is the first class of drugs used for chronic hepatitis C (CHC) treatment. NS3 inhibitors (PI) with low genetic barrier have been approved to be used in the CHC genotype 1 infections, and in the treatment of compensated liver disease including cirrhosis together with pegile interferon and ribavirin. Consequently, the development of drug resistance during DAA treatment of CHC is a major problem. NS3 resistant variants can be detected before treatment as they c...
Source: Mikrobiyoloji Bulteni - June 3, 2017 Category: Microbiology Tags: Mikrobiyol Bul Source Type: research
Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda.
CONCLUSIONS: HCV treatment regimens including interferon or ribavirin may precipitate PCT relapse. Hydroxychloroquine may be useful to prevent such relapses. In this limited experience, DAA were not associated with PCT relapse. Studies are needed to examine DAA as a primary PCT treatment in HCV-infected patients.
PMID: 28641714 [PubMed - in process] (Source: The American Journal of the Medical Sciences)
Source: The American Journal of the Medical Sciences - June 1, 2017 Category: General Medicine Authors: Singal AK, Venkata KVR, Jampana S, Islam FU, Anderson KE Tags: Am J Med Sci Source Type: research
Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.
Conclusions: In this study, we first found that sPD-L1 was increased in patients with CHC. Our results indicate that the level of serum sPD-L1 might be associated with the progression of CHC and the generation of hepatocellular carcinoma.
PMID: 28539815 [PubMed - in process] (Source: International Journal of Medical Sciences)
Source: International Journal of Medical Sciences - May 26, 2017 Category: Biomedical Science Tags: Int J Med Sci Source Type: research
Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.
CONCLUSION: The SVR rate was 42% with telaprevir- or boceprevir-based triple therapy in real-world practice. Low platelets and advanced fibrosis were associated with treatment failure and relapse.
PMID: 28469811 [PubMed - in process] (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - May 5, 2017 Category: Gastroenterology Tags: World J Hepatol Source Type: research
Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study
ConclusionDespite a high rate of treatment discontinuation (including loss to follow-up), self-reported adherence to treatment was good and virologic cure rates were similar to those reported in large real-world cohorts. Our findings suggest that people with a history of injecting drug use should be considered for treatment of chronic HCV infection, and highlight the need for improvements in patient support to boost retention in care and, in turn, help to prevent reinfection and transmission.Clinical trial registrationClinicaltrials.gov identifier, NCT01980290.FundingJanssen Pharmaceuticals. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - May 5, 2017 Category: Infectious Diseases Source Type: research
The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir ‐based regimens
ConclusionsAlthough the risk for AKI was lower than for patients treated with TVR/BOC‐based regimens, AKI was seen during 11% of SOF‐based regimens and was mostly reversible. Patients with ascites and patients using NSAIDs have an increased risk for AKI during SOF‐based antiviral therapy. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - May 3, 2017 Category: Drugs & Pharmacology Authors: R. Maan, S. H. Al Marzooqi, J. S. Klair, J. Karkada, O. Cerocchi, M. Kowgier, S. M. Harrell, K. D. Rhodes, H. L. A. Janssen, J. J. Feld, A. Duarte ‐Rojo Tags: ORIGINAL ARTICLE Source Type: research
Efficacy and safety of telaprevir with natural human interferon beta and ribavirin in Japanese chronic hepatitis C patients with depression
ConclusionThis study showed that an addition of TVR to IFN‐beta/RBV therapy raised SVR in previous treated and untreated genotype 1 and previous treated genotype 2 HCV infected patients with depression. (Source: Hepatology Research)
Source: Hepatology Research - May 1, 2017 Category: Internal Medicine Authors: Hiromitsu Kumada, Satoshi Mochida, Makoto Nakamuta, Fumitaka Suzuki, Takashi Yagi, Ryuji Takasaki, Masao Okai, Naohiro Kamiya, Yasushi Okada, Saya Hirota, Madori Orihashi, Miyoko Ochi, Kazuaki Chayama Tags: Original Article Source Type: research
Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.
CONCLUSION: The high cure rate of multi-DAA treatment of HCV is offset by the high costs of the DAAs, such that the cost per cure from TT to multi-DAA therapy has been relatively constant. In order to cure more patients, either additional financial resources will need to be allocated to the treatment of HCV or drug costs will need to be reduced.
PMID: 28425406 [PubMed - in process] (Source: Annals of Hepatology)
Source: Annals of Hepatology - April 22, 2017 Category: Gastroenterology Tags: Ann Hepatol Source Type: research
The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data
Conclusion: We found that despite the introduction of the breakthrough designated triple therapies with telaprevir or boceprevir in 2011, there was no increase of prevalence or incidence between 2010 and 2011. (Source: European Journal of Gastroenterology and Hepatology)
Source: European Journal of Gastroenterology and Hepatology - March 29, 2017 Category: Gastroenterology Tags: Original Articles: Hepatitis Source Type: research
Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial)
ConclusionsThese results highlight an improvement in both physical and mental HRQL during HCV treatment, but no major improvement in physical HRQL after treatment end, when comparing PEG-IFN-free regimens with PEG-IFN-containing regimens. This suggests that in the PEG-IFN-free regimens era, screening and comprehensive care of comorbidities and residual somatic symptoms during treatment, and especially after HCV clearance, are still needed to improve patient outcomes. (Source: The Patient - Patient-Centered Outcomes Research)
Source: The Patient - Patient-Centered Outcomes Research - March 28, 2017 Category: Global & Universal Source Type: research
Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C.
CONCLUSION: Both TVR- and SMV-based triple therapies can be successfully used to treat patients aged 66 years or older with genotype 1b chronic hepatitis C. Genotyping of the IL28B indicates a potential to achieve SVR in these difficult-to-treat elderly patients.
PMID: 28261382 [PubMed - in process] (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - March 8, 2017 Category: Gastroenterology Tags: World J Hepatol Source Type: research
Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment.
In conclusion, given the lifethreatening character of these complications, close monitoring is mandatory in patients under PIs based therapy to promptly detect serious hematological toxicities and to carefully evaluate treatment discontinuation. Prospective studies assessing the usefulness of RBV in the era of new IFN-free combinations are needed.
PMID: 28233734 [PubMed - in process] (Source: Annals of Hepatology)
Source: Annals of Hepatology - February 28, 2017 Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin.
We report the first case of an HCV infected patient treated for 12 wk with the combination of sofosbuvir/ledipasvir plus ribavirin who developed a miliary tuberculosis (TB) infection while on therapy. The patient was a 65-year-old woman, who referred malaise, asthenia, hyporexia, 7 kg weight loss, productive cough, evening fever and night sweats, right after finishing the treatment. The chest computed tomography-scan revealed a superior mediastinal widening secondary to numerous lymphadenopathies with extensive necrosis and bilateral diffuse lung miliary pattern with little subsequent bilateral pleural effusion, highly sug...
Source: World Journal of Hepatology - February 22, 2017 Category: Gastroenterology Tags: World J Hepatol Source Type: research
Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting.
CONCLUSION: In patients treated with DAAs for infection with HCV genotypes 1-4, variables favoring achievement of SVR included an age of <45 years, a body mass index of <25 kg/m(2), absence of cirrhosis, a fibrosis score of 0-2, and being TN.
PMID: 28213381 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - February 22, 2017 Category: Drugs & Pharmacology Authors: Bach TA, Zaiken K Tags: Am J Health Syst Pharm Source Type: research
